ELUCID
Based in the Boston biotech and medtech hub, Elucid is focused on improving the accuracy, experience, & cost-effectiveness of cardiovascular diagnostic imaging by leveraging machine learning. Elucid's main product, ElucidVivo, is the first-ever, FDA-cleared, histologically-validated software for evaluating plaque vulnerability from a single CTA to inform risk of event (heart attack or stroke) & treatment selection. Additionally, Elucid works with pharmaceutical companies, providers, and research organizations to provide quantitative image analysis services.
ELUCID
Industry:
Analytics Biotechnology Medical Device
Founded:
2013-01-01
Address:
Boston, Massachusetts, United States
Country:
United States
Website Url:
http://www.elucid.com
Total Employee:
51+
Status:
Active
Contact:
617-329-9487
Email Addresses:
[email protected]
Total Funding:
49.73 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail GoDaddy DNS Google Google Cloud COVID-19 DMARC Shutterstock
Similar Organizations
Enlitic
Enlitic builds AI deep learning products to streamline radiologists' workflows and improve healthcare diagnosis.
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Spero Therapeutics
Spero Therapeutics is developing first in class therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
IAG Capital Partners
IAG Capital Partners investment in Series B - Elucid
Aphelion Capital
Aphelion Capital investment in Series B - Elucid
Bold Brain Ventures
Bold Brain Ventures investment in Series B - Elucid
Biovision Ventures
Biovision Ventures investment in Series B - Elucid
BlueStone Venture Partners
BlueStone Venture Partners investment in Series B - Elucid
MedTex Ventures
MedTex Ventures investment in Series B - Elucid
MedTex Ventures
MedTex Ventures investment in Series A - Elucid
Wolverine Venture Fund
Wolverine Venture Fund investment in Series A - Elucid
IAG Capital Partners
IAG Capital Partners investment in Series A - Elucid
Global Health Impact Fund
Global Health Impact Fund investment in Series A - Elucid
Key Employee Changes
| Date | New article |
|---|---|
| 2022-07-26 | Todd C. Villines, M.D. Joins Elucid as new Chief Medical Officer |
Official Site Inspections
http://www.elucid.com Semrush global rank: 4.86 M Semrush visits lastest month: 1.82 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
